ATTR amyloidosis

August 26, 2026 Advancing Earlier Diagnosis and Coordinated Care in ATTR-CM For patients with transthyretin amyloidosis with cardiomyopathy (ATTR-CM), the path to effective care often begins with a challenge: receiving the right diagnosis before the disease irreversibly advances. Read More ›
March 27, 2026 Five Things to Know about TRITON-CM & How Community Insight is Shaping the Future of ATTR- ... TRITON-CM, Alnylam's Phase 3 clinical trial evaluating nucresiran, a third-generation investigational RNAi therapeutic for transthyretin amyloidosis with cardiomyopathy (ATTR-CM), represents one of the largest global studies ever conducted in this disease. Read More ›
September 6, 2023 First Consensus Recommendations for Holistic Care of People Living With Hereditary ATTR Am ... The Amyloidosis Alliance has published the first-ever consensus recommendations for patient- and family-centred holistic care in ATTRv. Read More ›
September 6, 2021 Co-Creating with Patients, for Patients: Addressing Unmet Needs in Conversations about AT ... Collaborating with patient organizations and patients is an essential part of our efforts to support people living with a complex rare disease like... Read More ›
Subscribe to ATTR amyloidosis